AstraZeneca enters obesity market with $2b deal for GLP-1 candidateAstraZeneca has signed an exclusive license agreement with Shanghai-based biotech Eccogene for ECC5004, an early-stage investigational...
AGA: Not all patients should cease taking GLP-1 RAs prior to endoscopyThe American Gastroenterological Association (AGA) has released a rapid clinical practice update addressing the management of patients...
First participant dosed in Terns’ trial of TERN-601 oral GLP-1ra for treatment of obesityTerns Pharmaceuticals has announced that the first participant has been dosed in the Phase 1 clinical trial of TERN-601, the company’s...
Innovent starts Phase 2 Clinical Trial of mazdutide in Chinese adults with obesityInnovent Biologics has announced that the first participant has been successfully dosed in the higher-dose cohort of a phase 2 clinical...
LSG and RYGB-induced upregulation of apoA-IV is beneficial for insulin secretion and energy expenditure1 day ago
Tirzepatide reduced sleep apnoea severity by up to nearly two-thirds in adults living with OSA and obesity1 day ago